Donald Trump imposed a 100% tariff on patented drugs unless manufactured in the US, effective October 2025. India's generic pharma exports remain largely unaffected, and major Indian branded drug exporters already have US plants. However, India's $66 billion pharmaceutical industry is closely monitoring potential future tariffs on generics.